United States

Novartis AG (NVS)

NVS on New York Consolidated

9 Dec 2016
Change (% chg)

$2.15 (+3.18%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Latest Key Developments (Source: Significant Developments)

Mereo Biopharma to list on London's AIM
Monday, 6 Jun 2016 02:10am EDT 

Mereo Biopharma : Proposed admission to trading on AIM and a further capital raise of 14.8 mln stg . Proceeds of private placement and convertible loan will provide additional funds to 76.5 million stg committed in July 2015 . Private placement of its ordinary shares raising gross proceeds of 11.35 million stg at a price of 2.21 stg per ordinary share . A cash investment by existing shareholder novartis by way of a convertible loan, in amount of 3.46 million stg . Trading in Mereo's ordinary shares on AIM market is expected to commence at 8:00am on 9 June 2016 under ticker symbol "MPH" . RBC Capital Markets is acting as global coordinator, private placement agent and broker to company .Cantor Fitzgerald Europe is acting as nominated adviser, private placement agent and broker. Evercore is acting as financial adviser.  Full Article

Novartis reports 13.6 pct passive stake in Merus NV as of May 24, 2016
Friday, 3 Jun 2016 08:02am EDT 

Novartis AG :Reports 13.6 pct passive stake in Merus NV as of May 24, 2016 SEC fiilng.  Full Article

Eisai and Novartis enter deal to co-promote Lenvima with Everolimus in U.S.
Thursday, 2 Jun 2016 04:15pm EDT 

Eisai Inc : Under terms , Novartis and Eisai sales representatives will promote availability of this combination regimen to oncologists nationwide .Eisai enters into a collaboration agreement to co-promote Lenvima (lenvatinib) in combination with Everolimus in the U.S..  Full Article

Sandoz broadens pharma portfolio with addition of Euro-Pharm product line
Tuesday, 31 May 2016 10:00am EDT 

Sandoz Canada Inc: Sandoz broadens its pharmaceutical portfolio with acquisition of Euro-Pharm product line .Sandoz Canada says Sandoz AG acquires North American product portfolio of Euro-Pharm International Canada.  Full Article

Novartis CEO: Willing to sell Roche stake without premium
Wednesday, 25 May 2016 03:28am EDT 

Novartis : Novartis CEO Joe Jimenez says no change in approach to Roche stake, which is financial investment, will look at opportuinities that arise . CEO says would potentially exit roche stake without getting a premium, if the opportunity were right . Ceo says biosimilars taking longer than expected, due to legal obstacles . Novartis ceo says recognised 2 years ago had to shift company compliance culture, is eliminating speaker programmes for some mature products .Cfo Says First Priority Organic Growth, Then Grow Dividend In Swiss Francs, Then Bolt On acquisitions, then share buybacks.  Full Article

Novartis: Sandoz' biosimilar rituximab regulatory submission accepted by European Medicines Agency
Tuesday, 24 May 2016 01:15am EDT 

Novartis AG :Sandoz' biosimilar rituximab regulatory submission accepted by European Medicines Agency.  Full Article

China NT Pharma says co entered into asset purchase agreement with Novartis<1011.HK>
Wednesday, 18 May 2016 10:39am EDT 

China NT Pharma Group Co Ltd <1011.HK>: NT Pharma (as purchaser) entered into asset purchase agreement with Novartis . Purchase price would be in the aggregate sum of US$145 million . Co has made an application for the resumption of trading in the shares of co with effect from 9:00 a.m. on Thursday, 19 May 2016 .  Full Article

Genmab - PDUFA target action date of September 10 for Ofatumumab
Tuesday, 17 May 2016 04:03pm EDT 

Genmab A/S : Pdufa target action date of September 10, 2016 for Ofatumumab .Ofatumumab in combination with fludarabine and cyclophosphamide for relapsed CLL accepted for priority review by FDA.  Full Article

Novartis AG says Afinitor gets nod in EU for some GI, lung neuroendocrine tumors
Friday, 29 Apr 2016 07:50am EDT 

Novartis AG:Says afinitor recommended by chmp for European Union approval to treat select GI and lung neuroendocrine tumors.  Full Article

Novartis AG receives three FDA breakthrough therapy designations for Ilaris
Wednesday, 27 Apr 2016 01:15am EDT 

Novartis AG:Novartis receives three FDA breakthrough therapy designations for Ilaris to treat rare types of periodic fever syndromes.Says breakthrough therapy designations were granted based on pivotal phase iii trial.Novartis will work closely with FDA to expedite regulatory review of Ilaris for these conditions.  Full Article


Novartis' drug tops chemotherapy in untreated lung cancer patients

Novartis AG said its cancer drug, Zykadia, was twice as effective as chemotherapy in slowing the progression of a rare form of lung cancer in a late-stage study.